DLL3 expression predicts response and long-term outcome in small cell lung cancer patients treated with tarlatamab
Bingnan Zhang, Lingzhi Hong, Kaiwen Wang, Catherine Allison Stewart, Komal Shah, Wei-lien Wang, Alejandra Serrano, Luisa Maren Solis Soto, Robert J. Cardnell, Alexa Halliday, Mitchell Parma, Elyse R. Lopez, Mukulika Bose, Cole Ruoff, Shafqat Ehsan, , Lauren A. Byers
This study shows DLL3 expression level predicts response and long-term survival in SCLC patients treated with tarlatamab.
bioRxiv · Sep 7, 2026 · PreprintCancer Biology